Aclaris Therapeutics Inc (ACRS) Receives Consensus Recommendation of “Hold” from Analysts

Aclaris Therapeutics Inc (NASDAQ:ACRS) has been assigned an average recommendation of “Hold” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $44.50.

Several equities analysts have recently issued reports on the company. Guggenheim assumed coverage on Aclaris Therapeutics in a research note on Thursday, February 8th. They set a “buy” rating and a $53.00 price target on the stock. BidaskClub lowered Aclaris Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Friday, February 2nd. Cantor Fitzgerald set a $50.00 price target on Aclaris Therapeutics and gave the company a “buy” rating in a research note on Monday, January 8th. Finally, Zacks Investment Research lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd.

Aclaris Therapeutics (ACRS) traded up $0.09 during trading on Tuesday, reaching $19.10. The company’s stock had a trading volume of 226,400 shares, compared to its average volume of 372,152. The firm has a market capitalization of $586.17, a price-to-earnings ratio of -8.84 and a beta of 1.26. Aclaris Therapeutics has a one year low of $18.46 and a one year high of $33.25.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Schwab Charles Investment Management Inc. increased its holdings in Aclaris Therapeutics by 40.5% in the second quarter. Schwab Charles Investment Management Inc. now owns 61,765 shares of the biotechnology company’s stock valued at $1,676,000 after purchasing an additional 17,804 shares during the last quarter. Cadence Capital Management LLC bought a new stake in Aclaris Therapeutics in the third quarter valued at about $689,000. Boothbay Fund Management LLC increased its holdings in Aclaris Therapeutics by 60.3% in the third quarter. Boothbay Fund Management LLC now owns 20,711 shares of the biotechnology company’s stock valued at $535,000 after purchasing an additional 7,791 shares during the last quarter. Citadel Advisors LLC increased its holdings in Aclaris Therapeutics by 620.6% in the third quarter. Citadel Advisors LLC now owns 242,016 shares of the biotechnology company’s stock valued at $6,247,000 after purchasing an additional 208,429 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in Aclaris Therapeutics by 60.8% in the second quarter. California State Teachers Retirement System now owns 35,696 shares of the biotechnology company’s stock valued at $968,000 after purchasing an additional 13,500 shares during the last quarter. Institutional investors and hedge funds own 92.47% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Aclaris Therapeutics Inc (ACRS) Receives Consensus Recommendation of “Hold” from Analysts” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2018/02/13/aclaris-therapeutics-inc-acrs-receives-consensus-recommendation-of-hold-from-analysts.html.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply